Diabetes patients can be a target for chronic kidney disease but can also take aim back: This is the message from AstraZeneca’s new Farxiga TV ad, which is pushing the drug’s new CKD label. There is ...

Type 2 diabetes is the most common form of diabetes. It can be diagnosed at any age and increases your risk of several other health problems. Farxiga (far-see-guh) is just one of the many prescription ...

Treatment with dapagliflozin led to a statistically significant improvement in HbA1c compared with placebo. The Food and Drug Administration (FDA) has expanded the approval of Farxiga ® (dapagliflozin ...

Both Farxiga (dapagliflozin) and Jardiance (empagliflozin) help manage blood sugar levels in adults and some children with type 2 diabetes. They also reduce risks associated with chronic kidney ...

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

FARXIGA significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type 2 diabetes WILMINGTON, Del.--(BUSINESS WIRE)-- High-level ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The approval was based on data from the DAPA-CKD trial, which compared dapagliflozin ...

WILMINGTON, Del.--(BUSINESS WIRE)--New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s ...

Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.--(BUSINESS WIRE)-- High-level results from the ...